Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 4/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.50 |
| ▸ | MMP1 | P03956 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 7/20 | 0.48 |
| ▸ | ITGA4 | P13612 | 7/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3697832 | 1.00 | HDAC1 (0.50) | HDAC1HDAC6MMP1ATML3MBTL1 | |
| SCHEMBL3701862 | 0.94 | ITGA4 (0.56) | ITGB1ITGA4ITGB7 | |
| SCHEMBL3704042 | 0.94 | ITGA4 (0.56) | ITGB1ITGA4ITGB7 | |
| SCHEMBL6128064 | 0.92 | MMP1 (0.48) | MMP1ATML3MBTL1ITGB1ITGA4 | |
| SCHEMBL7539474 | 0.92 | MMP1 (0.48) | MMP1ATML3MBTL1ITGB1ITGA4 | |
| SCHEMBL8739536 | 0.87 | HDAC1 (0.52) | HDAC1HDAC6MMP1ATML3MBTL1 | |
| SCHEMBL3695364 | 0.82 | ACE (0.49) | — | |
| SCHEMBL7544573 | 0.82 | ACE (0.49) | — | |
| SCHEMBL3695367 | 0.82 | ACE (0.49) | — | |
| SCHEMBL7541630 | 0.82 | ITGB1 (0.48) | HDAC1HDAC6MMP1ITGB1ITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| EP-2640689-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | Novartis AG (CH) | 2013-09-25 | — | — | EP | disclosed |
| WO-2012065953-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP INHIBITORS | NOVARTIS AG (CH) | 2012-05-24 | — | — | WO | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | HDAC1 449/4885HDAC6 213/4885MMP1 1708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.